The Vertiflex procedure is a minimally invasive spinal surgery that places a small titanium spacer between the bony projections on the back of your vertebrae (called spinous processes) to relieve pressure on compressed nerves. It’s designed specifically for people with lumbar spinal stenosis, a narrowing of the spinal canal that causes leg pain, numbness, or cramping when standing or walking. The spacer, officially called the Superion Interspinous Spacer, is an FDA-approved Class III medical device made from titanium alloy.
How the Spacer Works
Lumbar spinal stenosis squeezes the nerves in your lower back, especially when you stand upright or lean backward. That’s why people with this condition often feel relief when they sit down or lean forward over a shopping cart. Those positions naturally open up space in the spinal canal.
The Vertiflex spacer mimics that effect permanently. A small tube about the size of a dime is advanced between two spinous processes in your lower back. The implant is deployed through the tube and locks into place, acting as a physical wedge that prevents those bones from compressing together. This keeps the spinal canal slightly open and takes pressure off the nerves, even when you’re standing or walking. The approach is sometimes called “indirect decompression” because the spacer creates more room for the nerves without removing any bone or tissue.
What Happens During the Procedure
The Vertiflex procedure is performed through a single small incision in the lower back, typically using local anesthesia with sedation rather than general anesthesia. The surgeon uses real-time imaging (fluoroscopy) to guide the placement of the spacer. Because no bone is removed, no muscles are cut, and the spine’s natural structure stays intact, the procedure is significantly less invasive than traditional decompression surgery like a laminectomy. Most patients have it done in an outpatient surgical center and go home the same day.
Who Is a Candidate
The procedure targets a specific group of patients: those with moderate lumbar spinal stenosis who experience neurogenic claudication, the hallmark symptom pattern of leg pain, heaviness, or cramping that worsens with standing and walking and improves with sitting or bending forward. Candidates typically have imaging (MRI or CT scan) confirming stenosis at one or two levels in the lumbar spine.
The Vertiflex spacer is generally not appropriate for people with severe osteoporosis, since the device relies on the strength of the spinous processes to hold it in place. Patients with significant spinal instability, fractures, or tumors at the treatment level are also typically excluded. It’s positioned as a middle-ground option for people who haven’t found enough relief from conservative treatments like physical therapy, injections, and medications, but want to avoid the larger recovery of open spine surgery.
Recovery Timeline
Recovery is considerably faster than traditional spinal surgery. During the first two to four weeks, you’ll have some basic restrictions: no lifting over 15 pounds, limited sitting to 30 minutes at a time, and avoiding twisting or bending your lower back beyond a neutral position. The initial goal is wound healing and gradually building your walking tolerance to at least 10 minutes twice a day. Outpatient physical therapy typically begins during this phase.
Between four and six weeks, you’ll progress to functional strengthening and can start lifting heavier loads. By six weeks, most patients have no restrictions on activity. Compared to a traditional laminectomy, which can require weeks of more significant limitations and a longer return to full activity, this is a noticeably compressed timeline.
Clinical Outcomes and Satisfaction
In the FDA’s pivotal clinical trial, 75.6% of patients who received the Superion spacer achieved a meaningful reduction in leg pain (at least a 20-point improvement on a 100-point pain scale) at two years. Patient satisfaction was high: 86.2% reported being satisfied or somewhat satisfied at 24 months, and about 83% said they would have the procedure again.
Those numbers are encouraging, but they come with important context. The reoperation rate was 20% at two years and 25.8% over longer follow-up. That means roughly one in four patients eventually needed an additional procedure, whether a revision, removal, or conversion to a more traditional surgery. This is a meaningful consideration when weighing your options.
Risks and Complications
The most notable risk is spinous process fracture, which occurred in 11.6% of patients in the FDA trial. These are small cracks in the bony projections that anchor the spacer, and most happened within the first six months. The fractures don’t always cause symptoms, but they can affect how well the device works.
Other reported complications included:
- Back pain: 26.3% of patients
- Leg pain: 19.5%
- Returning stenosis symptoms at the treated level: 18.4%
- Buttock and groin pain: 11.1%
- Device migration or dislodgement: less than 1%
Some of these adverse events, particularly back and leg pain, may reflect the underlying condition rather than a complication of the device itself. Still, the fact that nearly one in five patients experienced a return of stenosis symptoms at the same spinal level suggests the spacer doesn’t work for everyone long-term.
Cost and Insurance Coverage
The Vertiflex procedure is billed under a specific insurance code (CPT 22869) for interspinous spacer implantation. Medicare has covered the procedure since 2018, when CMS established a payment rate of approximately $10,381 for the outpatient surgical center setting. The device is classified as “device-intensive,” meaning a large portion of the reimbursement goes toward the implant itself. Private insurance coverage varies by plan, so verifying benefits with your insurer before scheduling is worth the call.
Vertiflex Compared to Traditional Surgery
The main appeal of the Vertiflex procedure is that it’s far less disruptive than a laminectomy, the traditional surgical approach for spinal stenosis. A laminectomy involves removing part of the vertebral bone to decompress the nerves directly. It’s effective but requires a larger incision, more tissue disruption, general anesthesia, and a longer recovery.
Minimally invasive decompression approaches like Vertiflex offer shorter procedure times, less blood loss, and shorter (or no) hospital stays. The tradeoff is durability. The 25.8% reoperation rate for the Superion spacer means a quarter of patients may eventually need further intervention, and some of those will end up having the laminectomy they were trying to avoid. For patients who are poor candidates for major surgery due to age or other health conditions, the Vertiflex procedure can still be a valuable option, offering meaningful relief with a lower-risk profile even if the results aren’t permanent for everyone.